Mark B. Effron

7.1k total citations
118 papers, 3.4k citations indexed

About

Mark B. Effron is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Mark B. Effron has authored 118 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Cardiology and Cardiovascular Medicine, 45 papers in Surgery and 15 papers in Internal Medicine. Recurrent topics in Mark B. Effron's work include Antiplatelet Therapy and Cardiovascular Diseases (65 papers), Acute Myocardial Infarction Research (49 papers) and Coronary Interventions and Diagnostics (26 papers). Mark B. Effron is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (65 papers), Acute Myocardial Infarction Research (49 papers) and Coronary Interventions and Diagnostics (26 papers). Mark B. Effron collaborates with scholars based in United States, United Kingdom and Canada. Mark B. Effron's co-authors include Myron L. Weisfeldt, Peter R. Freund, W L Maughan, Eric J. Topol, Tracy Y. Wang, Barry S. George, Dominick J. Angiolillo, Marjorie E. Zettler, Eric D. Peterson and Lawrence A. Barr and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Mark B. Effron

110 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark B. Effron United States	30	2.4k	1.5k	487	411	375	118	3.4k
Morimasa Takayama Japan	31	2.8k 1.2×	1.2k 0.8×	450 0.9×	474 1.2×	817 2.2×	254	3.8k
Jindřich Špinar Czechia	24	2.2k 0.9×	928 0.6×	266 0.5×	518 1.3×	164 0.4×	117	3.1k
Beth Davison Weatherley United States	24	2.3k 1.0×	926 0.6×	684 1.4×	185 0.5×	312 0.8×	34	3.1k
Sibu P. Saha United States	24	887 0.4×	1.5k 1.0×	312 0.6×	360 0.9×	256 0.7×	108	3.4k
Joseph Lindsay United States	31	2.7k 1.1×	1.6k 1.1×	348 0.7×	140 0.3×	811 2.2×	140	4.0k
William C. Oliver United States	35	1.4k 0.6×	1.7k 1.1×	352 0.7×	456 1.1×	122 0.3×	93	3.6k
Bruce J. Leavitt United States	38	3.4k 1.4×	2.2k 1.5×	110 0.2×	448 1.1×	392 1.0×	100	5.1k
Gregory A. Nuttall United States	35	1.3k 0.5×	1.9k 1.3×	390 0.8×	371 0.9×	86 0.2×	118	4.0k
Jan‐Henk E. Dambrink Netherlands	30	3.3k 1.4×	2.0k 1.3×	271 0.6×	298 0.7×	1.2k 3.1×	87	4.0k
Volkhard Kurowski Germany	24	1.6k 0.7×	903 0.6×	292 0.6×	336 0.8×	783 2.1×	60	2.6k

Countries citing papers authored by Mark B. Effron

Since Specialization

Citations

This map shows the geographic impact of Mark B. Effron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Effron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Effron more than expected).

Fields of papers citing papers by Mark B. Effron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark B. Effron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Effron. The network helps show where Mark B. Effron may publish in the future.

Co-authorship network of co-authors of Mark B. Effron

This figure shows the co-authorship network connecting the top 25 collaborators of Mark B. Effron. A scholar is included among the top collaborators of Mark B. Effron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark B. Effron. Mark B. Effron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benziger, Catherine P., Amanda Stebbins, Lisa Wruck, et al.. (2024). Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients. JAMA Cardiology. 9(9). 808–808. 3 indexed citations

Marquis‐Gravel, Guillaume, Hillary Mulder, Lisa Wruck, et al.. (2024). Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open. 14(8). e078197–e078197.

Mulder, Hillary, Lisa Wruck, E. Hope Weissler, et al.. (2023). Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. Journal of the American Heart Association. 12(13). e027899–e027899. 4 indexed citations

Girotra, Saket, Amanda Stebbins, Lisa Wruck, et al.. (2023). Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. Journal of the American Heart Association. 12(20). e030385–e030385.

Amin, Amit P., Tracy Y. Wang, Lisa A. McCoy, et al.. (2016). Impact of Bleeding on Quality of Life in Patients on DAPT. Journal of the American College of Cardiology. 67(1). 59–65. 44 indexed citations

Xian, Ying, Tracy Y. Wang, Lisa A. McCoy, et al.. (2015). Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation. 132(3). 174–181. 30 indexed citations

Wang, Tracy Y., Timothy D. Henry, Mark B. Effron, et al.. (2015). Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation Cardiovascular Interventions. 8(6). e001712–e001712. 13 indexed citations

Bagai, Akshay, Eric D. Peterson, Emily Honeycutt, et al.. (2012). Abstract 15573: In-Hospital Switching of ADP Receptor Inhibitors in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study. Circulation. 126. 4 indexed citations

Angiolillo, Dominick J., Juan J. Badimon, Jorge F. Saucedo, et al.. (2009). Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). Circulation. 120(18). 2 indexed citations

10.

Saucedo, Jorge F., Dominick J. Angiolillo, Andrew L. Frelinger, et al.. (2009). Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study. Circulation. 120(18).

11.

Herrmann, Howard C., Jiandong Liu, Bruce R. Brodie, et al.. (2008). Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI Hospitals. The American Journal of Cardiology. 102. 2 indexed citations

12.

Safcsak, Karen, Mark B. Effron, Tim Rickert, et al.. (2004). Safety Of Drotrecogin Alfa (Activated): Results Of XEUS, A Prospective Multicenter Observational Study. CHEST Journal. 126(4). 724S–724S. 5 indexed citations

13.

Bakhai, Ameet, et al.. (2002). Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. Circulation. 106(19). 518–518. 1 indexed citations

14.

Cox, DA, et al.. (2001). A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Journal of the American College of Cardiology. 37(2). 5 indexed citations

15.

Effron, Mark B., et al.. (1999). Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention. Circulation. 100(18). 104–104. 1 indexed citations

16.

Lincoff, A. Michael, et al.. (1998). Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3). Circulation. 98(17). 17–17. 15 indexed citations

17.

Effron, Mark B., et al.. (1998). Abciximab and alveolar hemorrhage - reply. New England Journal of Medicine. 339(25). 1862–1863. 2 indexed citations

18.

Katz, Stanley, et al.. (1998). Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial. Circulation. 98(17). 22–22. 5 indexed citations

19.

Effron, Mark B., et al.. (1998). Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial. Circulation. 98(17). 17–17. 1 indexed citations

20.

Brener, S., Lawrence A. Barr, Eric David Cohen, et al.. (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. Journal of the American College of Cardiology. 31. 54–54. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact